Diversified Trust Co Acquires 2,138 Shares of Insulet Corporation (NASDAQ:PODD)

Diversified Trust Co grew its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 144.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,622 shares of the medical instruments supplier's stock after purchasing an additional 2,138 shares during the period. Diversified Trust Co's holdings in Insulet were worth $951,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in PODD. Board of the Pension Protection Fund lifted its holdings in shares of Insulet by 6.3% in the 1st quarter. Board of the Pension Protection Fund now owns 1,700 shares of the medical instruments supplier's stock worth $446,000 after purchasing an additional 100 shares in the last quarter. Perpetual Ltd acquired a new position in Insulet during the first quarter worth $3,097,000. PDS Planning Inc bought a new position in shares of Insulet in the first quarter valued at $208,000. Robeco Institutional Asset Management B.V. lifted its stake in shares of Insulet by 257.8% in the first quarter. Robeco Institutional Asset Management B.V. now owns 84,708 shares of the medical instruments supplier's stock valued at $22,245,000 after buying an additional 61,031 shares in the last quarter. Finally, Golden State Wealth Management LLC grew its holdings in shares of Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock valued at $55,000 after buying an additional 177 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of analyst reports. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Citigroup reissued a "buy" rating and set a $380.00 price objective (up from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Wells Fargo & Company set a $322.00 price objective on Insulet in a research note on Monday, April 28th. The Goldman Sachs Group initiated coverage on Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price on the stock. Finally, Oppenheimer upped their price target on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $321.00.

Insider Activity

In other news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president owned 23,180 shares of the company's stock, valued at $7,382,134.60. This represents a 18.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.39% of the stock is currently owned by insiders.

Insulet Stock Performance

NASDAQ PODD traded down $14.19 during trading hours on Tuesday, reaching $299.99. 1,404,448 shares of the company were exchanged, compared to its average volume of 716,587. Insulet Corporation has a 1 year low of $173.00 and a 1 year high of $329.33. The business's 50 day simple moving average is $300.32 and its 200-day simple moving average is $278.15. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $21.11 billion, a P/E ratio of 53.96, a P/E/G ratio of 2.80 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The company's revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 EPS. On average, equities research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.